DE60336356D1 - Molekulare Determinanten des multiplen Myeloms und deren Verwendung - Google Patents

Molekulare Determinanten des multiplen Myeloms und deren Verwendung

Info

Publication number
DE60336356D1
DE60336356D1 DE60336356T DE60336356T DE60336356D1 DE 60336356 D1 DE60336356 D1 DE 60336356D1 DE 60336356 T DE60336356 T DE 60336356T DE 60336356 T DE60336356 T DE 60336356T DE 60336356 D1 DE60336356 D1 DE 60336356D1
Authority
DE
Germany
Prior art keywords
multiple myeloma
lytic
lesions
bone
bone disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60336356T
Other languages
English (en)
Inventor
John D Shaughnessy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Arkansas
Original Assignee
University of Arkansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Arkansas filed Critical University of Arkansas
Application granted granted Critical
Publication of DE60336356D1 publication Critical patent/DE60336356D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
DE60336356T 2002-12-05 2003-12-04 Molekulare Determinanten des multiplen Myeloms und deren Verwendung Expired - Lifetime DE60336356D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43104002P 2002-12-05 2002-12-05

Publications (1)

Publication Number Publication Date
DE60336356D1 true DE60336356D1 (de) 2011-04-21

Family

ID=32507666

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60336356T Expired - Lifetime DE60336356D1 (de) 2002-12-05 2003-12-04 Molekulare Determinanten des multiplen Myeloms und deren Verwendung

Country Status (11)

Country Link
US (1) US7459437B2 (de)
EP (2) EP1913952B1 (de)
JP (2) JP4874549B2 (de)
AT (1) ATE500837T1 (de)
AU (1) AU2003302926A1 (de)
CA (1) CA2507496C (de)
DE (1) DE60336356D1 (de)
ES (1) ES2362681T3 (de)
MX (1) MXPA05006033A (de)
PT (1) PT1913952E (de)
WO (1) WO2004053063A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7811750B2 (en) * 2002-12-05 2010-10-12 Board Of Trustees Of The University Of Arkansas Molecular determinants of myeloma bone disease and use thereof
WO2005070448A2 (en) * 2004-01-21 2005-08-04 Five Prime Therapeutics, Inc. Methods of use for secreted frizzled-related protein 3 (sfrp-3) in the prevention and treatment of disease
AU2005267722B2 (en) * 2004-08-04 2009-10-08 Amgen Inc. Antibodies to Dkk-1
WO2006061430A2 (en) * 2004-12-10 2006-06-15 Proskelia Bone metastasis markers as a target regulating bone metastasis and bone development
JP2006217844A (ja) * 2005-02-09 2006-08-24 Univ Of Tokyo Ｄｋｋ１の遺伝子、蛋白質及び抗体を用いた癌の診断・モニター方法及び治療方法
AR060017A1 (es) 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
CN101517096B (zh) 2006-03-13 2013-10-16 上海市肿瘤研究所 Dkk-1蛋白在癌症诊断中的应用
ES2526928T3 (es) 2008-04-30 2015-01-16 The Governing Council Of The University Of Toronto Uso de SFRP-3 en la evaluación de la insuficiencia cardíaca
SG175881A1 (en) 2009-05-12 2011-12-29 Pfizer Blocking anti-dkk-1 antibodies and their uses
CA2800018C (en) * 2010-05-21 2021-09-28 Universitaet Fuer Bodenkultur Wien Compositions for use in treating or diagnosing bone disorders and/or cardiovascular disorders
CA2840687C (en) 2011-07-01 2020-04-28 Dana-Farber Cancer Institute, Inc. Discovery of a somatic mutation in myd88 gene in lymphoplasmacytic lymphoma
EP2744916A4 (de) 2011-07-13 2015-06-17 Primeradx Inc Multimodale verfahren zur simultanen erkennung und quantifizierung mehrerer nukleinsäuren in einer probe
AU2014318614B2 (en) 2013-09-12 2021-01-07 Dana-Farber Cancer Institute Inc. Methods for evaluating and treating Waldenstrom's macroglobulinemia
AU2014360426B2 (en) * 2013-12-06 2020-05-07 Dana-Farber Cancer Institute, Inc. Methods to distinguish Waldenstrom's Macroglobulinemia from IgM monoclonal gammopathy of undetermined significance
CA2932351A1 (en) 2013-12-13 2015-06-18 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
JP2019518006A (ja) 2016-04-29 2019-06-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｍｙｄ８８変異型疾患における治療標的としてのｈｃｋ

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1161445A2 (de) * 1999-03-05 2001-12-12 Millennium Pharmaceuticals, Inc. Menschliche dickkopf-verwandte proteine und nukleinsäuremoleküle und deren verwendungen
CN1387537A (zh) * 1999-09-13 2002-12-25 惠氏公司 应用分泌型卷曲相关蛋白的药用组合物和方法
EP1395285A4 (de) * 2001-05-17 2005-06-01 Genome Therapeutics Corp Reagenzien und verfahren zur modulation von dkk-vermittelten wechselwirkungen
US20040038860A1 (en) 2002-05-17 2004-02-26 Allen Kristina M. Reagents and methods for modulating dkk-mediated interactions

Also Published As

Publication number Publication date
MXPA05006033A (es) 2006-03-08
US20040137489A1 (en) 2004-07-15
EP1913952B1 (de) 2011-03-09
EP1913952A1 (de) 2008-04-23
EP1567663A4 (de) 2006-04-19
WO2004053063A3 (en) 2004-11-25
WO2004053063A2 (en) 2004-06-24
JP2012046535A (ja) 2012-03-08
CA2507496C (en) 2014-11-04
CA2507496A1 (en) 2004-06-24
JP2006512911A (ja) 2006-04-20
JP5432966B2 (ja) 2014-03-05
PT1913952E (pt) 2011-04-14
ATE500837T1 (de) 2011-03-15
ES2362681T3 (es) 2011-07-11
AU2003302926A1 (en) 2004-06-30
EP1567663A2 (de) 2005-08-31
JP4874549B2 (ja) 2012-02-15
US7459437B2 (en) 2008-12-02
AU2003302926A8 (en) 2004-06-30

Similar Documents

Publication Publication Date Title
ATE500837T1 (de) Molekulare determinanten des multiplen myeloms und deren verwendung
Acevedo et al. Variability of systemic and oro-dental phenotype in two families with non-lethal Raine syndrome with FAM20C mutations
Cicuttini et al. Genetics of osteoarthritis.
Kato et al. Sodium fluoride inhibits MMP-2 and MMP-9
Zakai et al. Racial differences in venous thromboembolism
Kawasaki et al. SCPP gene evolution and the dental mineralization continuum
Hočevar et al. The possible influence of genetic aetiological factors on molar–incisor hypomineralisation
Kantaputra et al. Heterozygous mutation in the SAM domain of p63 underlies Rapp-Hodgkin ectodermal dysplasia
ATE357440T1 (de) Benzodiazepin-substituierte piperdine zur verwendung in der behandlung von cardiovaskulären erkrankungen
Swamy et al. Effect of some clinically used proteolytic enzymes on inflammation in rats
Frisk et al. Goltz syndrome in males: A clinical report of a male patient carrying a novel PORCN variant and a review of the literature
Gong et al. Polyalanine repeat expansion mutation of the HOXD13 gene in a Chinese family with unusual clinical manifestations of synpolydactyly
Noto et al. Dyskeratosis congenita associated with leukoplakia of the tongue
Ebersole et al. Comparative analysis of gene expression patterns for oral epithelium-related functions with aging
Kjaer et al. HOXD13 polyalanine tract expansion in classical synpolydactyly type Vordingborg
DE60305665D1 (de) Verbessertes verfahren zur herstellung von polymeren zusammensetzungen auf polysiloxan-basis zur verwendung in medizinischen geräten
Wang et al. Long-term change of disease behavior in Papillon-Lefevre syndrome: seven years follow-up
Colletti et al. Epidermal nevus and ameloblastoma: a rare association
Allende et al. A genetic study of cathepsin C gene in two families with Papillon–Lefèvre syndrome
Avcin et al. Early-onset osteoarthritis due to otospondylomegaepiphyseal dysplasia in a family with a novel splicing mutation of the COL11A2 gene.
Mohammadi-Asl et al. A novel pathogenic variant in the FZD6 gene causes recessive nail dysplasia in a large Iranian kindred
Ng et al. Dissecting the development of Dupuytren disease through human genetics
Shehzad et al. Detection of single nucleotide polymorphism rs2013162 of IRF6 gene in patient with cleft lip and palate
Van Pham Tissue Engineering and Regenerative Medicine
Avina Fierro et al. A case of complete cutaneous syndactyly of the toes with non-syndromic phenotype